Loading…
Loading…
State Street SPDR S&P Telecom ETF earns a strong buy rating, driven by 80% twelve-month price returns and robust AI-powered demand trends. XTL's portfolio is concentrated in high-growth communication equipment and alternative carrier industries, offsetting weakness in integrated and wireless telecom holdings. Top holdings like Viasat, Extreme Networks, and Ciena have delivered triple-digit or near-triple-digit returns, benefiting from secular AI and data center demand.
expands its IP portfolio to clinical-stage biopharmaceutical assets XTL Biopharmaceuticals (XTL) Completes the Acquisition of Psyga Bio and Establishes Psychedelic Biotechnology Platform At a historic juncture and with unprecedented regulatory tailwinds in the US, XTL completes its strategic transformation and becomes a dedicated company in the field of global psychedelic medicine; operations will focus on an advanced clinical pipeline, a licensed GMP manufacturing facility, and a unique intellectual property (IP) library. HERZLIYA, ISRAEL, June 30, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd.
RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated May 18, 2026, notifying the Company that since the Company has not yet filed its Annual Report on Form 20-F for the year ended December 31, 2025, it no longer complies with Nasdaq's Listing Rule Listing Rule 5250(c)(1) which requires companies to timely file all required periodic financial reports with the SEC.
Designed to provide broad exposure to the Communication Services ETFs category of the market, the State Street SPDR S&P Telecom ETF (XTL) is a smart beta exchange traded fund launched on 01/26/2011.
Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum
Telecom ETF XTL hits a 52-week high, soaring about 149% from lows. Backed by 5G, AI-driven demand & defensive strength -- momentum suggests more upside ahead.
Amazon.com, Inc.'s $11.6 billion acquisition of Globalstar highlights surging demand for space-focused telecom, boosting XTL, where GSAT is the largest holding. I maintain a buy rating on the State Street SPDR S&P Telecom ETF, citing pristine momentum, an attractive 19.8x P/E, and a PEG near 1.0 amid a bullish technical setup. XTL's high small-cap exposure (60%) and low yield (0.95%) make it a tactical, growth-oriented telecom play rather than a defensive income vehicle.
RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, par value NIS0.1 per share (the "ADS Ratio"), from the current ADS Ratio of one (1) ADS to one hundred (100) ordinary shares, to a new ADS Ratio of one (1) ADS to four hundred (400) ordinary shares (the "ADS Ratio Change"). The Company anticipates that the ADS Ratio Change will be effective on March 25, 2026 (the "Effective Date").